News archive
2008
2008.11.25
SARomics receives ”Forska&Väx” grant from VINNOVA for development of the ProPHECY™ technology.
2008.11.10
SARomics Biostructures introduces services for academic groups.
Press release
SARomics Biostructures introduces services for academic groups
Lund, November 10, 2008 – The Lund-based structural biology contract research company SARomics Biostructures AB announced today that they will expand their range of services to include academic groups. Compared to corporate customers the academic groups will gain access to protein crystallization and protein structure determination services for prices, which should prove highly competitive with the traditional model of academic collaboration.
SARomics Biostructures has since 2006 provided structural biology services to the pharmaceutical and biotechnology industries. Typical projects include structure determination of protein-inhibitor complexes, where access to structural information increases the molecular understanding and enables faster project executions.
The recent development in low volume and high-throughput protein crystallization together with recent advances in synchrotron-based x-ray crystallography technologies have drastically reduced the time and effort required for relatively straightforward structure determinations, as well as reducing by approximately a factor of ten the amount of material required for initial crystallization trials. Through an agreement with MAX-lab, the Swedish national synchrotron radiation laboratory, SARomics Biostructures can access crystallization robotics and synchrotron beamlines free of charge for academic projects. Therefore, our services can be offered for a reduced price for non-commercial work.
SARomics Biostructures has, together with two different research groups at Lund University, recently determined the crystal structures of human galectin-3 in complex with two novel inhibitors to an unusually high resolution and of a bacterial carbohydrate binding module with two carbohydrate ligands. These two projects validated our business model where non-commercial structures could be determined for a fee ranging between 25 000 - 50 000 SEK. These prices are very competitive in relation to the costs of determining such structures through traditional academic collaborations, with their associated salaries, overheads and material costs.
2008.11.10
SARomics Biostructures determines protein-ligand crystal structures. Read More »
2008.09.01
SARomics ProPHECY™ technology successfully used in the design of potent antimicrobial peptides.
Press release
SARomics ProPHECYTM technology successfully used in the design of potent antimicrobial peptides
Lund, September 1, 2008 – SARomics AB announced today that together with researchers at Lund University and Uppsala University they have successfully used their ProPHECYTM technology for the rational design of potent antimicrobial peptides.
The work that will be published in the scientific journal Biochemistry describes a novel approach comprising selective amino acid changes based on structural considerations in an amphipathic peptide template, a biological and in silico evaluation of the resulting peptides, followed by a global analysis of interdependence of biophysical parameters and antimicrobial as well as hemolytic activity (cell toxicity). By utilizing a low number of amino acid substitutions at strategic positions in the original peptide template, guided by the ProPHECYTM analysis, they were able to develop peptides, which, in contrast to the parent peptide, exerted a significant antimicrobial activity on the disease causing bacteria Staphylococcus aureus. The work provides for the first time, predictive tools not only for antimicrobial activity but also for eukaryotic cell toxicity, as well as insights into the mechanisms governing selectivity towards different bacteria.
The new findings will be presented September 2, 2008, in the latest issue of the journal Biochemistry (Pasupuleti et. al., Rational Design of Antimicrobial C3a Analogues with Enhanced Effects against Staphylococci Using an Integrated Structure and Function- Based Approach, Biochemistry, 47, 35, 9057-9070, 2008, http://dx.doi.org/10.1021/bi800991e).
About ProPHECYTM
SARomics AB’s proprietary ProPHECYTM technology, allows the systematic optimization of biomolecular properties. The method is based upon the application of multivariate regression methods to correlate novel computed physicochemical descriptors with experimentally determined properties. This greatly reduces the effort, time and cost to optimize one or several targeted properties.
2008.08.29
SARomics determines protein-inhibitor crystal structures. Read more »
2008.05.22
SARomics Biostructures enters new collaboration agreement with Active Biotech, Lund, Sweden.
2008.05.20
SARomics launches ProPHECY™ which is a technology that enables the systematic optimization of biomolecular properties. Read more »
2008.04.03
SARomics Biostructures enters collaboration agreement with MAX-lab, Lund, Sweden, enabling access to MAX-lab’s facilities.
2008
2008.11.25
SARomics receives ”Forska&Väx” grant from VINNOVA for development of the ProPHECY™ technology.
2008.11.10
SARomics Biostructures introduces services for academic groups.
Press release
SARomics Biostructures introduces services for academic groups
Lund, November 10, 2008 – The Lund-based structural biology contract research company SARomics Biostructures AB announced today that they will expand their range of services to include academic groups. Compared to corporate customers the academic groups will gain access to protein crystallization and protein structure determination services for prices, which should prove highly competitive with the traditional model of academic collaboration.
SARomics Biostructures has since 2006 provided structural biology services to the pharmaceutical and biotechnology industries. Typical projects include structure determination of protein-inhibitor complexes, where access to structural information increases the molecular understanding and enables faster project executions.
The recent development in low volume and high-throughput protein crystallization together with recent advances in synchrotron-based x-ray crystallography technologies have drastically reduced the time and effort required for relatively straightforward structure determinations, as well as reducing by approximately a factor of ten the amount of material required for initial crystallization trials. Through an agreement with MAX-lab, the Swedish national synchrotron radiation laboratory, SARomics Biostructures can access crystallization robotics and synchrotron beamlines free of charge for academic projects. Therefore, our services can be offered for a reduced price for non-commercial work.
SARomics Biostructures has, together with two different research groups at Lund University, recently determined the crystal structures of human galectin-3 in complex with two novel inhibitors to an unusually high resolution and of a bacterial carbohydrate binding module with two carbohydrate ligands. These two projects validated our business model where non-commercial structures could be determined for a fee ranging between 25 000 - 50 000 SEK. These prices are very competitive in relation to the costs of determining such structures through traditional academic collaborations, with their associated salaries, overheads and material costs.
2008.11.10
SARomics Biostructures determines protein-ligand crystal structures. Read More »
2008.09.01
SARomics ProPHECY™ technology successfully used in the design of potent antimicrobial peptides.
Press release
SARomics ProPHECYTM technology successfully used in the design of potent antimicrobial peptides
Lund, September 1, 2008 – SARomics AB announced today that together with researchers at Lund University and Uppsala University they have successfully used their ProPHECYTM technology for the rational design of potent antimicrobial peptides.
The work that will be published in the scientific journal Biochemistry describes a novel approach comprising selective amino acid changes based on structural considerations in an amphipathic peptide template, a biological and in silico evaluation of the resulting peptides, followed by a global analysis of interdependence of biophysical parameters and antimicrobial as well as hemolytic activity (cell toxicity). By utilizing a low number of amino acid substitutions at strategic positions in the original peptide template, guided by the ProPHECYTM analysis, they were able to develop peptides, which, in contrast to the parent peptide, exerted a significant antimicrobial activity on the disease causing bacteria Staphylococcus aureus. The work provides for the first time, predictive tools not only for antimicrobial activity but also for eukaryotic cell toxicity, as well as insights into the mechanisms governing selectivity towards different bacteria.
The new findings will be presented September 2, 2008, in the latest issue of the journal Biochemistry (Pasupuleti et. al., Rational Design of Antimicrobial C3a Analogues with Enhanced Effects against Staphylococci Using an Integrated Structure and Function- Based Approach, Biochemistry, 47, 35, 9057-9070, 2008, http://dx.doi.org/10.1021/bi800991e).
About ProPHECYTM
SARomics AB’s proprietary ProPHECYTM technology, allows the systematic optimization of biomolecular properties. The method is based upon the application of multivariate regression methods to correlate novel computed physicochemical descriptors with experimentally determined properties. This greatly reduces the effort, time and cost to optimize one or several targeted properties.
2008.08.29
SARomics determines protein-inhibitor crystal structures. Read more »
2008.05.22
SARomics Biostructures enters new collaboration agreement with Active Biotech, Lund, Sweden.
2008.05.20
SARomics launches ProPHECY™ which is a technology that enables the systematic optimization of biomolecular properties. Read more »
2008.04.03
SARomics Biostructures enters collaboration agreement with MAX-lab, Lund, Sweden, enabling access to MAX-lab’s facilities.